Literature DB >> 10548386

Microcirculation and arterial hypertension.

E Vicaut1.   

Abstract

A large part of the pressure gradient takes place in the microvascular network (which corresponds to vessels less than 150 microns in diameter). Most of the changes in the peripheral resistance associated with hypertension affect the microvascular network. From the brief review presented here, it appears that the functional characteristics of arterioles are significantly modified in hypertension. Sensitivity to numerous vasoconstrictive substances is increased. Local ACE activity is considerably higher, and endothelium-dependent dilation is lower, in genetically hypertensive animals than in control models. The myogenic response, which represents the vasoconstriction of arterioles in response to a stepped increase in pressure, is also amplified by mechanisms dependent on both prostanoids and endothelin. Changes also affect the structure of the microvascular network. Morphological alterations in the arteriolar wall are not observed for all types of hypertension. Conversely, arteriolar and capillary rarefaction appears to be the most commonly observed change affecting the structure of the microvascular network. The first stage of rarefaction is functional and affects the number of vessels perfused but not the total number of vessels of the microvascular network. At this stage, potent dilators can induce a recruitment of microvessels, which may cancel the difference between the number of perfused vessels in hypertensive and normotensive animals. The second stage is the anatomical rarefaction corresponding to a decrease in arterioles and/or the total number or density of capillaries. Microvascular rarefaction has also been described in patients even in the early stages of hypertension. This led us to consider the microvascular network not only as one of the putative factors responsible for increased pressure but also as a key target of hypertension. Consequently, antihypertensive drugs should also be assessed and differentiated in terms of their efficacy in preventing or reversing the microcirculatory damage associated with hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548386

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  4 in total

Review 1.  Genetic determinants of vascular reactivity.

Authors:  Daniel Henrion; Joelle Benessiano; Marc Iglarz; Ivan Philip; Bernard I Levy
Journal:  Curr Hypertens Rep       Date:  2002-02       Impact factor: 5.369

2.  Nanoparticle inhalation alters systemic arteriolar vasoreactivity through sympathetic and cyclooxygenase-mediated pathways.

Authors:  Travis L Knuckles; Jinghai Yi; David G Frazer; Howard D Leonard; Bean T Chen; Vince Castranova; Timothy R Nurkiewicz
Journal:  Nanotoxicology       Date:  2011-08-10       Impact factor: 5.913

3.  PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats.

Authors:  Marilyn J Cipolla; Nicole Bishop; R Saman Vinke; Julie A Godfrey
Journal:  Stroke       Date:  2010-04-15       Impact factor: 7.914

4.  Capillary rarefaction in treated and untreated hypertensive subjects.

Authors:  Cynthia Cheng; Constantine Daskalakis; Bonita Falkner
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.